Compare Mesoblast Limited (MESO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Recursion Pharmaceuticals Inc — how do they compare? Mesoblast Limited trades at $15.13 (market cap $1.90B), while Recursion Pharmaceuticals Inc trades at $3.83 (market cap $2.07B). The key difference: Mesoblast Limited and Recursion Pharmaceuticals Inc are close in size by market cap, and Mesoblast Limited is more actively traded (143,591 versus 44,195,371). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 12 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MESO | RXRX | |
|---|---|---|
Market Cap | $1.90B | $2.07B |
Volume | 143,591 | 44,195,371 |
Sector | Health | Health |
52-Week High | $20.96 | $6.79 |
52-Week Low | $13.19 | $2.84 |
Typical Hold Time | 12 Days | 22 Days |
Enterprise Value | $1.98B | $1.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.13, up 5.0% in the last 24 hours, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $102.14 million in 2025, though revenue grew substantially to $120 million in 2026. Recent milestones include completing a Phase 3 trial for chronic back pain treatment and achieving $115 million in RYONCIL net revenue for the full year 2026, indicating a transition to a commercial-stage company.
The outlook is mixed; strong revenue growth and pipeline progress offer upside potential, but persistent losses and high cash burn pose significant risks. Analyst sentiment is cautiously optimistic with a 45% buy rating, yet the stock faces execution and regulatory hurdles in bringing new therapies to market.
Recursion Pharmaceuticals (RXRX) trades at $3.83, up 20.06% today, showing strong momentum despite recent volatility. The stock exhibits a bullish technical signal with moving averages supporting upward movement, though oscillators remain neutral. Fundamentally, the company continues to operate at a loss with negative profit margins and high cash burn, though recent earnings have shown some improvement with two beats in the last four quarters. Analyst sentiment is mixed with 40% buy ratings, while institutional interest remains active.
The outlook remains speculative with significant execution risk given the company's negative profitability and high cash consumption. Investment opportunity lies in the AI-driven drug discovery platform and pipeline expansion, particularly in oncology and rare diseases. Key risks include prolonged cash burn, competitive pressures in biotech, and the binary nature of clinical trial outcomes that could significantly impact valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
